DXYZ vs Fundrise VCX 2026: NAV Premiums, Holdings & Lockup

🔄 NAV update, August 28, 2026 — the denominator on this page has changed. Fundrise filed VCX's schedule of investments for June 30, 2026 on August 28, 2026: net assets $776,968,000 and NAV $21.70 per share, up 14.4% from the $18.97 reported for March 31, 2026. Premium figures on this page that were computed against $18.97 were correct for their dates, and are now computed against a superseded NAV. Against the June 30 figure, the August 28 close of $39.84 is a premium of 1.84x (83.6%), not the 2.10x (110.0%) the old denominator gives — a difference of about 26 percentage points. Full position-by-position breakdown, at cost and at mark: VCX's NAV is $21.70, not $18.97.

There are exactly two NYSE-listed closed-end funds in 2026 that retail investors can buy through a normal brokerage account to get pure-play exposure to a diversified basket of late-stage private technology companies: VCX (Fundrise Innovation Fund) and DXYZ (Destiny Tech100). Both hold positions in Anthropic, Databricks, OpenAI, and SpaceX. Both came out of the gate with extreme NAV premiums. Both have been the subject of bear cases and short reports.

Their stories diverged by exactly 24 months, which makes the comparison unusually clean. DXYZ's 2024-2026 trajectory is a near-controlled experiment for what VCX investors should expect over the next 24 months — including the August 13, 2026 lockup expiration, a sharper, all-at-once version of the staged lockup DXYZ went through in 2024.

I'm not going to pretend either fund is a clean buy. They're both structurally peculiar. But the comparison is genuinely useful for investors trying to size venture exposure in a brokerage account.

This is not investment advice. It is a structural analysis with primary sources.

Listing and Price Trajectory

VCX — March 2026

Fundrise's Innovation Fund listed on the NYSE on March 19-20, 2026, after a shareholder vote in February 2026 approved the public listing (the same vote rejected a proposed management fee increase that did not reach the supermajority threshold). The fund had been operating since July 2022 as a registered tender-offer fund with limited liquidity, reaching about $515M in net assets by late January 2026 (about 28.3 million shares at an $18.19 NAV; our arithmetic) and 100,000 individual investors.

The last NAV published before listing was $18.19 (January 29, 2026); at March 31, 2026 it was $18.97. The first trades were at significant premiums to NAV. By late March, the share price reached approximately $380 — a roughly 1,900% premium to the $18.97 March 31 NAV — turning a fund with about $679 million of net assets into a NYSE-listed entity valued at about $13.6 billion at the $380.00 record close (35.8 million shares; our arithmetic).

Then on March 26, 2026, Citron Research (Andrew Left) published a short report alleging that VCX's valuation was "disconnected from underlying assets," citing the 2023 SEC settlement against Fundrise (which paid $250,000 for "willfully" violating securities laws by paying 200+ influencers without disclosure), the fund's 0.42% marketing expense (0.42% of net assets in the proxy fee table; $1.35 million in the year to March 31, 2026, per the N-CSR), and the supply-shock risk from the lockup expiration (then scheduled for ~September 14, since accelerated to August 13, 2026).

VCX dropped approximately 31% on the day of the report, after trading as low as $182.01 intraday, 52% below the prior close. It then recovered to $94.55 at the May 1, 2026 close, about 5x NAV (a ~398% premium to $18.97). At the September 11, 2026 close of $33.50 it traded at 1.54x its $21.70 June 30 NAV (a 54.4% premium), and the median daily volume over the 20 sessions to September 11 was about 600,000 shares (our arithmetic).

DXYZ — March 2024 (The Two-Year Precedent)

Destiny Tech100 listed on the NYSE on March 26, 2024 — exactly two years before Citron's VCX report. NAV at listing was $4.84. The fund surged to $99.79 closing price on April 8, 2024, representing a roughly 2,000% premium to NAV — the highest closed-end-fund premium in U.S. history (the prior record was 1,235% in 1929, per Acadian Asset Management).

The compression that followed was rapid initially, then prolonged:

The compression occurred even as DXYZ's underlying NAV grew dramatically — NAV was $19.93/share at December 31, 2025, up 209.6% in 2025, and $34.30 at June 30, 2026. This is the punchline: DXYZ's price compression wasn't because the fund did badly; the underlying private companies' valuations rocketed up. The compression happened because the market priced out the irrational premium investors paid in April 2024.

For VCX investors today, this is the reference scenario. Even if VCX's holdings (Anthropic, OpenAI, Databricks) post strong NAV growth over the next 24 months, the price compression is structurally separate from underlying performance.

Holdings and Overlap

VCX Holdings (March 31, 2026, Form N-CSR)

Plus positions across fintech, aerospace, gaming, software, healthcare, and proptech. The top three holdings (Anthropic + Databricks + OpenAI) represent 43.0% of net assets — a heavily concentrated AI portfolio. The fund's artificial-intelligence category is 58.6% of net assets (it includes Databricks); data infrastructure is 4.3%; data-center mortgage-backed securities 9.7% and a money-market fund 5.6% (all at March 31, 2026).

For deeper context on the underlying VCX holdings and the lockup risk specifically, see our standalone VCX review and the August 13, 2026 lockup expiration analysis. For the disclosed record of Fundrise-affiliated selling ahead of that date, see the VCX Form 144 record.

DXYZ Holdings (Q4 2025)

DXYZ's largest single position at year-end 2025 (SpaceX, 16.1%) was about the size of VCX's largest (Anthropic, 16.5% at March 31, 2026), but DXYZ's weight falls off faster: its next five holdings were 3-4% each, and it holds 32 names, with heavy long-tail exposure across space, defense, fintech, gaming, and consumer technology.

The fund's largest 2026 addition was a $107M Anthropic position (cost) acquired January 26, 2026 — the largest single investment in Destiny's history. By June 30, 2026 it was carried at $235.7 million, 14.4% of net assets, DXYZ's largest position. DXYZ also added CHAOS Industries and Hermeus during the year.

The Four Overlapping Holdings

VCX and DXYZ both have exposure, mostly through SPVs and co-investment vehicles, to:

• Anthropic — 16.5% of VCX (March 31, 2026) vs 14.4% of DXYZ (June 30, 2026; its largest position, bought in January 2026)
• OpenAI — 12.4% of VCX vs sub-3.5% of DXYZ
• Databricks — 14.1% of VCX vs 1-4% of DXYZ (4.0% at December 31, 2025; 1.2% at June 30, 2026)
• SpaceX — 4.0% of VCX vs 10.6% of DXYZ at June 30, 2026 (16.1% at December 31, 2025; our arithmetic across its three SpaceX vehicles)

For an investor who specifically wants AI exposure, VCX is the more concentrated bet. For an investor who wants space/defense exposure, DXYZ is the heavier weighting. Neither fund hedges the other meaningfully — overlap on names but very different risk profiles.

Fees and Expense Ratios

VCX Fee Structure

• Management fee: 1.85% of average daily net assets
• Marketing expense: ~0.42% of net assets in the proxy fee table ($1.35 million in the year to March 31, 2026) — flagged by Citron as concerning
• Other expenses: Estimated total expense ratio in the high 2% range, but precise figures depend on the most recent N-CSR filing

A shareholder vote in February 2026 considered raising the management fee but the proposal failed (did not reach the supermajority threshold). Two of the three proposals on the same ballot passed: the NYSE listing itself, and the lockup terms. The fee proposal's failure is itself a notable governance signal — VCX shareholders pushed back on operator economics.

DXYZ Fee Structure

• Pre-listing fee: 2.00% per annum (monthly accrual)
• Post-listing fee (current): 0.625% per quarter = 2.50% annualized of average gross assets

Note the structural difference: VCX charges on net assets; DXYZ charges on gross assets. Gross-asset fees are higher in absolute dollar terms when the fund uses any leverage or has receivables that boost gross above net.

The Comparison

Both funds are expensive by traditional ETF standards (where 0.10-0.30% is typical) but reasonable by interval-fund standards (ARK Venture Fund / ARKVX runs 2.90% net / 3.49% gross). The structural fee gap favors VCX, but neither fund is competitive with mainstream tech ETFs on fee alone — investors are paying for access to private companies, not for low-cost beta.

The Lockup Question — VCX's Specific Risk

This is the central tactical issue for any VCX investor in 2026, and the question that DXYZ's history doesn't directly answer.

VCX Lockup Mechanics

Per Fundrise's help documentation, VCX shares purchased before February 20, 2026 are restricted — held at Computershare, could not be transferred to brokerage or sold until the lockup expired. The lockup was originally set to expire September 14, 2026; on July 24, 2026 the Fund moved it to August 13, 2026, and locked shares could trade from August 14 (Form 8-K, exhibit 99.1).

Shares purchased after February 20, 2026 (and through the pre-listing window, capped at $10,000 per existing customer) were unrestricted — these were the shares floating on the NYSE before the unlock. Fundrise has not published the split; shares outstanding rose from about 28.3 million at January 29, 2026 to 35,797,138 at March 31, 2026, so part of the listed float was never locked.

Restricted holders include approximately 100,000 retail investors who held pre-IPO Innovation Fund shares. Many entered at NAV ($10.05 to $18.19 between March 2023 and January 2026, per the fund's filings). At the ~$92 price of early May they were sitting on roughly 5-9x paper gains; at the September 11, 2026 close of $33.50, roughly 1.8-3.3x (our arithmetic). The behavioral incentive is strong.

What DXYZ Tells Us

DXYZ had a lockup too, but a staged one: 25% of its pre-listing (SAFE-conversion) shares were free at listing and the rest unlocked in thirds 60, 120 and 180 days after listing, per its 2024 semi-annual report. Its premium went from ~2,000% to ~54% by the end of 2025, and not in a straight line (it was ~814% at the end of 2024). The compression was driven by speculative exhaustion plus underlying NAV growth that "earned into" the price.

VCX has the underlying-NAV-growth tailwind too (Anthropic potentially valued at $850-900B per April 2026 reports; OpenAI's most recent round at $852B; SpaceX targeting 2026 IPO at $1-1.5T). But VCX also had a single, all-at-once supply event on August 13, 2026.

On paper that made VCX's setup worse than DXYZ's: DXYZ's lockup released in three stages, VCX's all at once. In the event, VCX's premium widened after the unlock rather than compressing (see VCX after the unlock).

For Fundrise's official commentary on the lockup, see Fundrise's help center. For the supply-side math of the 100,000-investor unlock, see our dedicated lockup analysis.

Andrew Left / Citron Short Report — VCX Specific

The Citron Research short report on VCX (published March 26, 2026 — exactly one week after VCX's NYSE debut) is a unique factor in the VCX story that DXYZ never faced.

Key Citron allegations:

1. The 2023 SEC settlement: Fundrise Advisors paid a $250,000 penalty after the SEC found it willfully violated the compliance and former cash solicitation provisions of Section 206(4) of the Investment Advisers Act and Rules 206(4)-3 and 206(4)-7, in paying over 200 social media influencers and newsletter publishers to solicit clients
2. The 0.42% marketing expense (0.42% of net assets in the proxy fee table; $1.35 million in the year to March 31, 2026) — Citron urged the SEC to investigate undisclosed marketing
3. The August 13, 2026 lockup risk and the structural supply-overhang
4. The "valuation disconnected from underlying assets" critique — pure premium-to-NAV math

VCX's price reaction was severe: down ~31% on the day of the report, ~50% peak-to-trough during the session.

Andrew Left's federal case: The legal context matters. Left was charged with 19 federal counts (1 securities fraud scheme + 17 securities fraud + 1 false statements) filed July 25, 2024 in the Central District of California, alleging a $16M+ market manipulation scheme. On June 1, 2026 a Los Angeles federal jury found him guilty of the securities fraud scheme and 12 of the 16 other counts (13 of 17); sentencing was scheduled for August 31, 2026. The Citron-vs-VCX storyline is inseparable from Left's broader credibility.

DXYZ comparable: No major Citron, Kerrisdale, Spruce Point, or comparable activist short report has been published on DXYZ. Bear cases exist in long-form research (Seeking Alpha "DXYZ: Despite Owning SpaceX And OpenAI, This Fund Is A Sell"; Morningstar "Not Destiny's Child") but no formal short campaign. DXYZ's two-year compression happened without a coordinated short-seller catalyst — making the "natural" compression that much more striking.

NAV Methodology — How These Funds Mark Their Privates

DXYZ NAV Cadence

DXYZ marks NAV quarterly (March 31, June 30, September 30, December 31). Public securities are valued at last-traded close on the period end. Private investments are fair-valued via methodologies including liquidation basis, present value of cash flows, income approach, or NAV from underlying SPVs as a practical expedient. The Fair Valuation Committee meets frequently and may update marks between quarters if a portfolio company has a public funding event (new round, secondary, IPO).

DXYZ files Form N-CSR semi-annually with the SEC. The FY2025 report shows a 209.59% NAV increase for 2025, a year that included the December 2025 SpaceX ($800B) and Databricks ($134B) rounds; Anthropic's February 2026 and OpenAI's March 2026 rounds came after it (DXYZ bought its Anthropic exposure on January 26, 2026). The June 30, 2026 semi-annual report puts NAV at $34.30.

VCX NAV Cadence

The exact VCX NAV cadence and methodology require pulling the most recent N-CSR or N-2 filing directly from SEC EDGAR. Closed-end funds under Rule 2a-5 typically use quarterly fair-value methodology consistent with industry standards. As of May 1, 2026, the most recently authorized public NAV figure was approximately $19 — used as the denominator for premium calculations throughout this article.

Comparison Table

The Investor Playbook

If You Currently Hold VCX

The August 13, 2026 lockup (tradeable August 14) was the dominant variable, and it has passed; former restricted holders can now sell at any time. Even believers in the long-term thesis benefit from rebalancing some gains in any premium-to-NAV environment because the premium is mathematically unstable.

For holders buying on the secondary market today: at the September 11, 2026 close you are paying 1.54x NAV ($33.50 against the $21.70 June 30 NAV; our arithmetic) for a fund that has already been through its unlock. This is still high-uncertainty positioning.

If You Currently Hold DXYZ

The post-mortem is largely complete. DXYZ's premium has compressed from 2,000% to 64% over 24 months. The underlying NAV is up 210% year-over-year, which justifies a meaningful premium. The remaining 64% premium reflects continued retail demand for diversified private-tech exposure in a daily-liquid wrapper.

The next catalysts are the underlying funding rounds (SpaceX targeting 2026 IPO at $1-1.5T; Anthropic potential $850-900B round) and any incremental Anthropic-position purchases (after the January 2026 purchase at a $107M cost). Position sizing here is more conventional than VCX positioning.

If You're Comparing VCX vs DXYZ Today

The cleanest framework is exposure preference plus risk tolerance:

• You want maximum AI exposure (Anthropic + OpenAI): VCX. AI is 58.6% of VCX's net assets, and the top three holdings are 43% (March 31, 2026). DXYZ is much more diversified.
• You want maximum SpaceX exposure (and 2026 IPO catalyst): DXYZ. SpaceX was 10.6% of DXYZ at June 30, 2026 (16.1% at year-end 2025, when it was the largest position). VCX had 4.0% SpaceX at March 31, 2026.
• You want lower fees: VCX (1.85% on net vs DXYZ's 2.50% on gross).
• You want lower premium-to-NAV risk: DXYZ. Its compression already happened gradually. VCX's premium fell from ~353% in June to 68.1% on August 12, the last session before its lockup lifted — and then went the other way once holders could actually sell, reaching about 120% at the August 21 close, the widest of the whole unlock event.
• You want broader diversification: DXYZ (32 companies vs VCX's 25+ named portfolio companies).
• You want a tokenized non-US version: VCX has VCXx via Kraken's xStocks platform (launched March 27, 2026). DXYZ has no tokenized analog.

The Hybrid Approach

For investors who want venture exposure but are uncomfortable with either fund's specific risks, a 50-50 split between VCX and DXYZ captures both fund's overlapping holdings (Anthropic, OpenAI, Databricks, SpaceX) at reduced concentration risk. The pricing risks are imperfectly correlated — VCX's lockup-specific supply event is largely uncorrelated with DXYZ's organic premium dynamics — so the 50-50 is genuinely diversifying within the narrow private-tech-CEF category.

For comparison vs other private-markets exposure vehicles (ARK Venture Fund / ARKVX, Sweater, Privateshares), see Best Real Estate Crowdfunding for Accredited Investors.

Pros and Cons

VCX

DXYZ

Frequently Asked Questions

Sources

• Fundrise Innovation Fund (VCX) on fundrise.com
• Fundrise help — restricted vs unrestricted Innovation Fund shares
• Fundrise help — 6-month lockup period
• BusinessWire — VCX participates in OpenAI's $122B funding round (April 1, 2026)
• BusinessWire — VCXx tokenization launch via Kraken xStocks (March 27, 2026)
• Yahoo Finance — Fundrise Innovation Fund NYSE listing
• Yahoo Finance DXYZ quote page
• Stockanalysis DXYZ
• Morningstar — DXYZ: This Closed-End Fund Is Not Destiny's Child
• Acadian Asset — Stupidity is our destiny: Historic CEF overpricing
• Axios — DXYZ and the closed-end fund puzzle
• YCharts — DXYZ premium/discount to NAV
• Stocktwits — DXYZ is the new VCX
• destiny.xyz Tech100 2025 Semi-Annual Report
• Benzinga — VCX Crashes 50% on Citron Short Report
• Stocktwits — Citron Shorts VCX
• Citron Research
• DOJ — United States v. Andrew Left case page
• SEC Litigation Release LR-26056 — Andrew Left / Citron Capital
• DOJ press release — Activist short seller charged in $16M scheme
• CNBC — Anthropic closes $30B funding round at $380B valuation
• TechCrunch — Anthropic potentially $50B at $900B
• CNBC — OpenAI closes $122B at $852B (March 31, 2026)
• Bloomberg — SpaceX $800B insider share deal (December 2025)
• Databricks PR — $134B Series L (December 2025)
• Financial Samurai — Fundrise Innovation Fund NYSE Listing
• ARK Venture Fund (ARKVX) — official page
• Closed-End Fund Association — Discounts and Premiums

Internal links: Fundrise VCX Review 2026 · VCX Lockup Expiration, August 13 2026 · The VCX Form 144 Record · Fundrise Review 2026 · Fundrise Portfolio Comparison 2026 · Is Fundrise Pro Worth It? · Best Real Estate Crowdfunding for Accredited Investors · Bankruptcy-Remote Real Estate Crowdfunding Platforms